5-HT 2 Receptor Distribution Shown by [ 18 F] Setoperone PET in High-Functioning Autistic Adults

Department of Radiology, the Thompson Center, University of Missouri, MO, USA.
The Journal of Neuropsychiatry and Clinical Neurosciences (Impact Factor: 2.82). 03/2012; 24(2):191-7. DOI: 10.1176/appi.neuropsych.11080202
Source: PubMed


The serotonergic system is implicated in disordered emotional behavior. Autism is characterized by impaired processing of emotional information. The serotonergic (5-HT) system is also critically involved in brain development, and abnormal brain synthesis of serotonin is observed in autism. Furthermore, whole blood and platelet serotonin have been reported to be elevated in autism. The authors examined the CNS serotonin system in autism in vivo. 5-HT2 receptors were visualized by PET imaging of [18F]setoperone-binding in this pilot study of 6 high-functioning autistic adults and 10 matched-control participants. Autism subjects had less thalamic [18F]setoperone binding than controls, when covaried for age, but no difference reached significance in other areas. A negative relationship between thalamic binding and history of language impairment was also observed. Further studies will be needed to gain a clearer picture of the role of the 5-HT system in autism.

Download full-text


Available from: Darin D Dougherty,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: 5-Hydroxytryptamine 2A receptors (5-HT2A-Rs) are widely expressed in the brain and have been implicated in mood and behavior. Based on the use of atypical antipsychotics in schizophrenia, antagonism of 5-HT2A-Rs initially emerged as a potential intervention capable of reducing the incidence of extrapyramidal symptoms, while exerting an effective antipsychotic action. More recently, highly selective 5-HT2A-R antagonists have been evaluated in the treatment of a wide range of other psychiatric disorders. Areas covered: The aim of the current review is to present important clinical studies investigating the potential therapeutic effects of 5-HT2A-R antagonists in both primary psychiatric disorders, such as schizophrenia and mood disorders, as well as in psychiatric manifestations of neurodegenerative disorders. We present an overview of 5-HT2A-Rs in normal brain function and the rationale for use in (neuro) psychiatric disease based on significant findings from genetic association studies, neuroimaging data and postmortem studies. The majority of the studies relate to schizophrenia, depression, anxiety, obsessive compulsive disorder and psychosis in Parkinson's disease and Alzheimer's disease. To date, there is sparse literature on 5-HT2A-Rs in Gilles de la Tourette syndrome, attention deficit hyperactivity disorder, eating disorders and autism spectrum disorders. The authors conclude by reviewing recent clinical trials investigating highly selective 5-HT2A-R antagonists in schizophrenia, psychosis in Parkinson's disease, insomnia and generalized anxiety. Expert opinion: Despite the potential, to date, 5-HT2A-R antagonists have not made an impact in the management of psychiatric disorders and psychiatric symptoms of neurodegenerative conditions.
    Expert Opinion on Investigational Drugs 02/2013; 22(4). DOI:10.1517/13543784.2013.769957 · 5.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This chapter contains sections titled: Imaging and Pharmacodynamics Biomarkers in Drug Development General Considerations for Development of 11C- and 18F-labeled PET Tracers Radiolabeling Compounds with 11C Radiolabeling Compounds with 18F PET Imaging in the Clinic, Research, and Drug Development PET Tracer Kinetic Modeling for Quantification of Tracer Uptake Concluding Remarks
    12/2013: pages 289-342;
  • [Show abstract] [Hide abstract]
    ABSTRACT: 2-Bromomethyl- and 2-iodomethyl-2,3-dihydrothiazolo[3,2-a]pyrimidin-5-ones are prepared via the reaction of 3-allyl-2-thiouracil derivatives with bromine or iodine chloride, respectively. The 6-bromo and 6-nitro derivatives are synthesized by an electrophilic substitution at C-6 of the thiazolopyrimidine system. As a result, novel 2,3-dihydrothiazolo[3,2-a]pyrimidin-5-one derivatives are obtained. Hydrogen halide elimination from the 2-halomethy1-2,3-dihydrothiazolo[3,2-a]pyrimidin-5-ones is also reported.
    Tetrahedron Letters 02/2014; 55(7):1384–1386. DOI:10.1002/chin.201431171 · 2.38 Impact Factor
Show more